comprising: a) providing a population comprising mesenchymal stromal cells; and b)
enhancing the population under conditions that allow the MSCs to loosely self-aggregate
and in the presence of cytokine to produce culture engineered MSCs (ce-MSCs). In an
embodiment, the cytokine is present at 0.1-15 ng/ml.